Trial
NCT01121757
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Duke University
Collaborators
Celgene
Condition
Follicular Lymphoma
Intervention
azacitidine
Why stopped
The study closed temporarily in February 2012 pending analysis of samples collected. In October, 2012, Celgene requested closure of the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-09-12